Skip to content

Effect of Repetetive Transcranial Magnetic Stimulation(RTMS) on Mild Cognitive Impairment (MCI)

Efficacy of Repetetive Transcranial Magnetic Stimulation(RTMS) on Mild Cognitive Impairment (MCI)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017011028199N2
Enrollment
16
Registered
2017-04-27
Start date
2017-02-19
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive disorder. Mild cognitive disorder

Interventions

Intervention 1: Intervention group 1: 8 patients in this study will be treated with RTMS 2-3 times per week for 8 weeks with every session lasts for 30 minutes. Device for induction of magnitude wave
Treatment - Devices
Placebo
Intervention group 1: 8 patients in this study will be treated with RTMS 2-3 times per week for 8 weeks with every session lasts for 30 minutes. Device for induction of magnitude wave is named Magnat
Intervention group 2: 8 patients will be initially treated with placebo for 8 weeks via pure voice without real magnitude wave cognitive tests. Cognitive tests will be performed at the end of the 8t

Sponsors

vice chancellor for research of Iran University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria : Patients with MCI(mild cognitive impairement) based on complaint of memory impairment with MMSE(mini mental status exam) score of more than 24 / 30 ? MCA(Montreal Cognitive Asessment)score of more than 26 / 30. Exclusion criteria : Dementia confirmed with MMSE score of less than 24 /30? MCA score of less than 26 / 30 ?Other treatable causes of dementia including serum B12 level below 200 Pg/ml ? hypothyroidism with thyroid stimulating hormone of above 6 uU/ml? any lesion on brain computed tomography scan explaining forgetfulness ? Depression rolled out in the recruited population with Beck screening test 14-28.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Evaluation of change in cognitive function. Timepoint: From one week before intervention & placebo to one week after intervention & placebo. Method of measurement: Questionnaire includes Mini Mental Cognitive Exam and Montreal Cognitive Assessment.

Secondary

MeasureTime frame
-. Timepoint: -. Method of measurement: -.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEnsieh Malekdar

Firoozgar hospital

THEFIRSTMAJID@YAHOO.COM info@ent-hns.org+98 21 8214 1718

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026